The study, presented at ESC Congress 2024 in London, confirmed that TAVR was associated with significantly better outcomes than surgery when treating female patients. The study, presented at ESC Congress 2024 in London, confirmed that TAVR was associated with significantly better outcomes than surgery when treating female patients. | | |
|
According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025. According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025. | | |
|
Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients. Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients. | | |
|
The sensors of certain FreeStyle Libre 3 devices are producing inaccurate glucose readings and should not be used. Two patient injuries have been reported. Abbott first reported the problem in July. The sensors of certain FreeStyle Libre 3 devices are producing inaccurate glucose readings and should not be used. Two patient injuries have been reported. Abbott first reported the problem in July. | | |
|
“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity. “No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity. | | |
|
HeartKey Rhythm was designed to help care teams keep up with the rising amount of ECG data they receive on a regular basis. HeartKey Rhythm was designed to help care teams keep up with the rising amount of ECG data they receive on a regular basis. | | |
|
Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted. Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted. | | |
|
Cardio-rheumatology clinics use a heart team-like approach to enhance care for patients with chronic conditions such as lupus, psoriasis and rheumatoid arthritis. "It's not just about cardiology," the director of one clinic explains. "We work closely with rheumatologists, dermatologists and even primary care physicians to provide comprehensive care." Cardio-rheumatology clinics use a heart team-like approach to enhance care for patients with chronic conditions such as lupus, psoriasis and rheumatoid arthritis. "It's not just about cardiology," the director of one clinic explains. "We work closely with rheumatologists, dermatologists and even primary care physicians to provide comprehensive care." | | |
|
In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time. In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time. | | |
|
Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024. Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024. | | |
|
